- André Muller appointed to Cellectis (CLLS, Financial) Board of Directors during June 2025 shareholders meeting.
- Shareholders approved 25 out of 26 resolutions with 57% voting rights exercised.
- Board members Pierre Bastid resigned and Axel-Sven Malkomes' term expired.
Cellectis (CLLS), a clinical-stage biotechnology company specializing in gene-editing therapies, convened its general shareholders meeting on June 26, 2025. The meeting, held at the Biopark auditorium in Paris, saw about 57% of voting rights exercised. Shareholders approved 25 out of 26 proposed resolutions, aligning with the board's recommendations, while resolution 24 was rejected.
The meeting marked significant changes within Cellectis' Board of Directors. André Muller, the current CEO of Idorsia Pharmaceuticals, was appointed as a new board member. With a rich background in pharmaceuticals, Muller brings valuable experience from his roles at Idorsia, Actelion Pharmaceuticals, and Pierre Fabre SA to Cellectis. Notably, the resignations of Pierre Bastid and the expiration of Axel-Sven Malkomes' term were formalized at this meeting.
Jean-Pierre Garnier, Chairman of the Board of Directors of Cellectis, expressed appreciation for the contribution of the departing board members and welcomed the addition of Muller, noting that his experience would be an invaluable asset to the company.
Cellectis, listed on Nasdaq under the ticker CLLS, is known for its pioneering gene-editing platform aimed at developing life-saving cell and gene therapies, particularly in oncology through allogeneic CAR T immunotherapies. The company's headquarters are located in Paris, France, with additional sites in New York and Raleigh, NC.
